Astrazeneca (AZN) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for Calquence, in combination with bendamustine and rituximab, as a treatment for adult patients with previously untreated mantle cell lymphoma.
The company said the recommendation was based on the results of a phase 3 trial, where the combination therapy demonstrated over 16 months of progression-free survival improvement compared with chemoimmunotherapy alone.
Astrazeneca also said no new safety signals were identified during the trial, and Calquence's safety and tolerability remained consistent with its known safety profile.
The company is currently evaluating Calquence as a single treatment and in combination with standard-of-care chemoimmunotherapy for the treatment of multiple B-cell blood cancers, according to the statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.